ID 31618
JaLCDOI
FullText URL
Author
Nishiya, Koji
Hisakawa, Naoko
Tahara, Kiyoshi
Matsumori, Akinori
Ito, Hiroyuki
Hashimoto, Kozo
Nakatani, Ko
Takatori, Kazuhiro
Abstract

To evaluate the efficacy and safety of additive triple disease modifying anti-rheumatic drug (DMARD) combination therapy of a low dose of sulfhydryl compounds inverted question markD-penicillamine, bucillamine or tiopronin inverted question mark, sulfasalazine (SSZ) and methotrexate (MTX) as a treatment for rheumatoid arthritis (RA) patients, we studied a total of 33 Japanese RA patients (6 males, 27 females). At 1 or 2 months after simultaneous administration of the 3 above-mentioned DMARDs was begun, significant improvements were seen in markers of joint inflammation, i.e., erythrocyte sedimentation rate and C-reactive protein in sera. At 6 months, clinical improvement judged by the physicians' overall assessment of joint symptoms and laboratory data was observed in 29 (88%) of the 33 RA patients. No marked effect was observed in the other 4 (12%) patients, however. We observed no significant adverse reaction to this therapy. This suggests that additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, SSZ and MTX could be a useful drug therapy for the treatment of RA patients, even those who are refractory.

Keywords
rheumatoid arthritis
joint inflammation
disease modifying anti-rheumatic drug
combination therapy
Amo Type
Brief Note
Published Date
1999-12
Publication Title
Acta Medica Okayama
Volume
volume53
Issue
issue6
Publisher
Okayama University Medical School
Start Page
275
End Page
279
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT